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% Cardiac death, % MI,% TLR, %
non TL-
TVR TLF, % TVF, %
Ultimaster 0.0 1.6 1.6 0.0 3.2 3.2
Xience 0.0 3.6 0.7 2.2 3.6 5.1
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Background: Improved early healing may reduce the risk of early stent thrombosis in
patients treated with drug eluting stents. Incomplete healing is found more frequently
after treatment for acute myocardial infarction, in patients with acute stent strut
malapposition and after treatment by speciﬁc stent types. Dual antiplatelet therapy is
used to balance the risk of incomplete healing but early discontinuation is rather
common and hard to predict at the primary intervention. We aim to evaluate and
compare early healing of an everolimus-eluting biodegradable polymer stent (Syn-
ergy, Boston Scientiﬁc, USA) having potential advantages in early healing with a
biolimus-eluting biodegradable polymer stent (BioMatrix NeoFlex, Biosensors,
Switzerland).
Methods: The study is a prospective, randomized dual center trial with one month
follow-up (Cohort A) or three months follow-up (Cohort B). Patients are random-
ized 1:1 to Synergy or Biomatrix Neoﬂex. A total of 160 patients are scheduled, 80
in each cohort. Inclusion criteria are stable angina pectoris, non-ST, or ST-elevation
myocardial infarction. Exclusion criteria are impaired renal function, severe vessel
tortuosity or severe systemic disease. Optical frequency domain imaging (OFDI,
Lunawave, Terumo, Jp) will be acquired at baseline and at follow-up or earlier in
case of a target vessel event. The primary endpoint is the Coronary Stent healing
Index, a combination of uncovered apposed and malapposed struts, excess neo-
intimal hyperplasia, acquired and persistent malapposition and size of the extra-stent
lumen. Frame level matching is performed for baseline adjusted analysis by expe-
rienced observers using semi-automated software analysis (QCU-CMS Research,
Leiden University Medical Center, The Netherlands). Clinical follow-up will be
continued up to 5 years.
Results: One-month OFDI follow-up (Cohort A) will be presented at TCT2014.
Conclusions: The study is designed to compare early healing in two different stents.
A potential difference may indicate improved early safety after stent implantation.
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Background: PCI with use of DES has been increasingly used in patients with high
risk acute coronary syndromes (STEMI/NSTEMI). However, controversies related to
their long-term safety in this complex patient population are still present. Therefore
safety and efﬁcacy of new, sirolimus-eluting stent coated with bioresorbable polymer,
Ultimaster DES(Terumo Corporation, Tokyo, Japan), in high risk acute coronary
syndrome (ACS) patients was assessed.
Methods: In the frame of a single-blind, randomized, multicentre CENTURY II
study, out of 1123 patients enrolled, 264 have been diagnosed with high risk ACS
and assigned randomly to treatment with Ultimaster (126) or Xience (138) DES.
Primary endpoint of the study was TLF at 9 months. All data were 100%
monitored and adverse events were adjudicated by an independent clinical event
committee.
Results: Baseline patient characteristics such as age, gender, presence of diabetes,
hypertension, dyslipidemia, family history of CAD, smoking, previous MI and
previous PCI were similar in both study arms. Also, there were no differences
noted in thrombus presence (10.1% vs 11.8%, p¼0.61) or bifurcation lesions
(10.2% vs 9.8%, p¼0.88). LAD was the most frequent target vessel and radial
access was used in >70% of cases, without difference between treatment arms.
Clinical outcomes at 4-months are shown in the table below. No signiﬁcant dif-
ferences were observed between the two stent arms. There were 2 patients with
subacute stent thrombosis in Ultimaster and 1 patient with 3 vessels of stent
thrombosis in Xience arm, resulting in low and similar ST rates (1.6% vs 0.7%,
p¼0.51).B174 JACC Vol 64/11/Suppl B j SeptemberConclusions: Short term safety and efﬁcacy of new Ultimaster DES was very similar
to the Xience DES in patients with high risk ACS. Follow up of patients is ongoing
and 1-year data will be available at the time of presentation.
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Background: Unlike any other current bioabsorbable drug-eluting stent, the MiStent
SES (Micell Technologies, Durham, NC) has a unique coating composition that al-
lows for continued drug elution after the rapid and complete absorption of polymer.
Crystalline sirolimus continues to maintain therapeutic drug tissue levels up to 9
months; 3 times longer than the presence of the polymer. The polymer coating is
eliminated from a thin-strut (64mm) cobalt chromium stent in 45-60 days with com-
plete tissue absorption within 90 days. Long-term clinical follow-up is important to
conﬁrm the continued safety of patients treated with DES in clinical practice. To date,
patients from two studies have completed 3 year follow-up.
Methods: The DESSOLVE I clinical trial is a ﬁrst-in-human study at 5 sites of 30
MiStent implanted patients; the DESSOLVE II clinical trial, is a 2:1 randomized study
of 184 patients conducted at 26 sites in evaluating the MiStent SES as compared to the
control stent, the Endeavor Sprint. In the trials, patients with discrete de novo lesions
up to 27 mm in length in native coronary arteries were enrolled. In-stent late lumen
loss (LLL) was evaluated in both trials and to date, patients have been followed for
clinical events annually for 3-years. All MACE events, deﬁned as all death, Q and
non-Q wave myocardial infarction and all target vessel revascularization were adju-
dicated by an independent clinical events committee.
Results: Follow-up for DESSOLVE I was complete for all available patients at 3-
years (29/29). No target lesion MACE events were reported through 3 years, however,
2 non-target vessel MIs were reported. In the DESSOLVE II trial, MACE for MiStent
and Endeavor was 4.3% versus 6.7% (p¼0.49) respectively at 9 months, 5.1% versus
8.3% (p¼0.51) at 12 months and 6.7% versus 13.3% (p¼0.167) at 2 years. Evaluation
of additional 3-year clinical outcomes of the MiStent SES for DESSOLVE II will be
presented.
Conclusions: The evaluation of a new DES (MiStent SES) with a distinctive coating
to provide continuous drug elution in the absence of polymer reveals sustained clinical
results through 3-years follow-up.
TCT-598
Randomized Comparison Between Self-Apposing Bare Metal AnD PaclitaxEl-
Eluting Coronary Stents For The Treatment Of SaPhenous Vein GrafTs (SVG):
Results From The ADEPT Trial
Alexander J. IJsselmuiden1, Giovanni Amoroso2, Paul Vermeersch3,
Pasi P. Karjalainen4
1Albert Schweitzer Hospital, Dordrecht, Netherlands, 2Onze Lieve Vrouwe Gasthuis,
Amsterdam, Netherlands, 3ZNA Middelheim, Antwerp, Belgium, 4Satakunta Central
Hospital, Pori, Finland
Background: The advantages of saphenous vein are well known for CABG: it is used
in 80% of these procedures. However Saphenous Vein Grafts (SVGs) get diseased
over time because of thrombosis, intimal hyperplasia and atherosclerosis. PCIs of
SVGs represent 10% of caseload in high volume cathlabs and carry increased risk
compared to PCI in native vessels. Previous studies comparing DES with BMS
showed reduced late lumen loss and target vessel revascularization, but also a higher
mortality rate for DES: at the start of this study, no consensus was available. Moreover
large lumen diameter and caliber change especially at the anastomosis site lead to
increased risk of under- / over- sizing with balloon-expandable stents. Self-expanding
stents could improve apposition after thrombus/debris resolution following PCI and
their deployment from distal to proximal could limit risk of distal embolization.
Methods: The Adept study, a randomized multicenter study, compares the safety and
performance of the STENTYS (STENTYS, France) coronary bare metal stent with the
Paclitaxel-eluting stent in Saphenous Vein Graft lesions. Patients are followed up at 1,
6 and 12 months post-procedure. The primary endpoint is in-stent late lumen loss at 6.
Secondary endpoints include MACE at 1, 6 and 12 months, binary restenosis at 6
months, and strut malapposition at 6 months (OCT substudy in 10 patients). Patients
with de-novo lesion in SVG (>50%stenosis), under optimal drug regimen, and with13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Randomized Trials
